Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Bevan

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
ISA Transactions|February 4, 2023
Data-driven H<sub>∞</sub> control of constrained systems: An application to bilateral teleoperation systemIbrahim Kucukdemiral, Hakan Yazici, Bilal Gormus, et al.
Current Protocols in Human Genetics|January 14, 2012
Interpretation of genomic copy number variants using DECIPHERManuel Corpas, Eugene Bragin, Stephen Clayton, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 16, 2016
Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell CarcinomaNicholas M Donin, Allan Pantuck, Pia Klöpfer, et al.
Urologic Oncology|April 1, 2015
Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trialKarim Chamie, Pia Klöpfer, Paul Bevan, et al.
Nucleic Acids Research|October 24, 2013
DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variationEugene Bragin, Eleni A Chatzimichali, Caroline F Wright, et al.
Journal of the American Society of Nephrology : JASN|April 20, 2000
Cellular and subcellular distribution of polycystin-2, the protein product of the PKD2 geneLukas Foggensteiner, A Paul Bevan, Ruth Thomas, et al.
International Journal of Oncology|September 19, 2014
Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer modelMiriam Zatovicova, Lenka Jelenska, Alzbeta Hulikova, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2016
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037Emma J Haagensen, Huw D Thomas, Wolfgang A Schmalix, et al.
Human Molecular Genetics|September 11, 2012
DECIPHER: web-based, community resource for clinical interpretation of rare variants in developmental disordersGanesh J Swaminathan, Eugene Bragin, Eleni A Chatzimichali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trialChaitanya R Divgi, Robert G Uzzo, Constantine Gatsonis, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
ISA Transactions|February 4, 2023
Data-driven H<sub>∞</sub> control of constrained systems: An application to bilateral teleoperation systemIbrahim Kucukdemiral, Hakan Yazici, Bilal Gormus, et al.
Current Protocols in Human Genetics|January 14, 2012
Interpretation of genomic copy number variants using DECIPHERManuel Corpas, Eugene Bragin, Stephen Clayton, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 16, 2016
Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell CarcinomaNicholas M Donin, Allan Pantuck, Pia Klöpfer, et al.
Urologic Oncology|April 1, 2015
Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trialKarim Chamie, Pia Klöpfer, Paul Bevan, et al.
Nucleic Acids Research|October 24, 2013
DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variationEugene Bragin, Eleni A Chatzimichali, Caroline F Wright, et al.
Journal of the American Society of Nephrology : JASN|April 20, 2000
Cellular and subcellular distribution of polycystin-2, the protein product of the PKD2 geneLukas Foggensteiner, A Paul Bevan, Ruth Thomas, et al.
International Journal of Oncology|September 19, 2014
Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer modelMiriam Zatovicova, Lenka Jelenska, Alzbeta Hulikova, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2016
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037Emma J Haagensen, Huw D Thomas, Wolfgang A Schmalix, et al.
Human Molecular Genetics|September 11, 2012
DECIPHER: web-based, community resource for clinical interpretation of rare variants in developmental disordersGanesh J Swaminathan, Eugene Bragin, Eleni A Chatzimichali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trialChaitanya R Divgi, Robert G Uzzo, Constantine Gatsonis, et al.
Pageof 3